Citas bibligráficas
Romero, J., Zavala, J. (2024). Aceptabilidad y barreras para el uso de la profilaxis preexposición al virus de la inmunodeficiencia humana en personas de alto riesgo que asisten al centro de salud México en Lima, mayo-julio 2024 [Universidad María Auxiliadora]. https://hdl.handle.net/20.500.12970/2328
Romero, J., Zavala, J. Aceptabilidad y barreras para el uso de la profilaxis preexposición al virus de la inmunodeficiencia humana en personas de alto riesgo que asisten al centro de salud México en Lima, mayo-julio 2024 []. PE: Universidad María Auxiliadora; 2024. https://hdl.handle.net/20.500.12970/2328
@misc{renati/1112360,
title = "Aceptabilidad y barreras para el uso de la profilaxis preexposición al virus de la inmunodeficiencia humana en personas de alto riesgo que asisten al centro de salud México en Lima, mayo-julio 2024",
author = "Zavala Villegas, Jorge Antonio",
publisher = "Universidad María Auxiliadora",
year = "2024"
}
Objective: to determine the barriers related to the acceptability for the use of oral pre-exposure prophylaxis (PrEP) in high-risk individuals attending the Mexico health center in Lima, may-july 2024. Materials and methods: a quantitative, observational, cross-sectional, prospective, and analytical study was conducted through a dichotomous survey directed to 300 patients of the Mexico health center, with the purpose of measuring the barriers for the acceptability of oral PrEP in HIV prevention. The data obtained were analyzed using bivariate, and univariate statistical methods. Measures of association were also determined. Results: associations were found between personal, community, and institutional barriers with the acceptability of oral PrEP. It was determined that patients who reject oral PrEP are 5.17 times more likely to experience personal barriers; 2.34 times more likely to experience community barriers and 2.33 times more likely to present barriers at the institutional level than those who accept it. Conclusion: there are barriers related to acceptability for the use of oral PrEP in high-risk patients attending the Mexico health center in Lima, may-july 2024.
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons